Current Medical Research and Opinion最新文献

{"title":"Impact of switching to bictegravir- or dolutegravir-based antiretroviral therapy on weight in people living with HIV during the COVID-19 pandemic.","authors":"Nardine Karam, Monica Douglas, Stanley Moy","doi":"10.1080/03007995.2025.2514761","DOIUrl":"10.1080/03007995.2025.2514761","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate weight change in people living with HIV (PLWH) who switched to dolutegravir (DTG)- or bictegravir (BIC)-based antiretroviral regimens compared to those who remained on regimens that did not contain integrase strand transfer inhibitors (INSTIs) during the COVID-19 pandemic.</p><p><strong>Methods: </strong>This retrospective cohort study included virologically-suppressed PLWH seen at an HIV clinic between 1 January 2020 to 31 December 2023. Patients aged 18 years and older were included if they switched from raltegravir- or elvitegravir-based to DTG- or BIC-based regimens (Group 1), from non-INSTI-based to DTG- or BIC-based regimens (Group 2), or remained on non-INSTI-based regimens (Group 3). Pregnant PLWH were excluded. The primary outcome was absolute weight change from index visit date to 6 and 12 months.</p><p><strong>Results: </strong>A total of 200 patients were included (<i>n</i> = 45 in Group 1, <i>n</i> = 26 in Group 2, and <i>n</i> = 129 in Group 3). Groups 1 and 2 experienced a median weight increase of 0.9 kg and 0.5 kg, respectively, from index to 12 months, while Group 3 experienced a median weight decrease of 1.1 kg from index to 12 months. Body mass index (BMI) increased from index to 12 months by a median of 0.5 kg/m² and 0.4 kg/m² in Groups 1 and 2, respectively, and decreased by a median of 0.4 kg/m² in Group 3. Hemoglobin A1c increased by a median of 0.1% in Groups 1 and 2 with no change in Group 3. Using mixed linear models adjusted for sex, age, and baseline BMI, there were no significant changes in adjusted mean weight, A1c, and LDL across the groups from index to 6 and 12 months. In Group 3, patients at the upper quartile of age were observed to experience a significant BMI decrease from index to 12 months (<i>p</i> = 0.008).</p><p><strong>Conclusion: </strong>Switching to BIC- or DTG-based regimens during the COVID-19 pandemic was not associated with weight gain in treatment-experienced, virologically-suppressed PLWH in this single-center study. The study findings may reassure clinicians who are hesitant about switching treatment-experienced patients to newer BIC- or DTG-containing regimens due to concerns about potential weight gain.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"779-787"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between carotid sublayers thickness and cardiac alterations in dialysis patients.","authors":"Demétrio C S Vieira, Agnes N Santos, Vinicius C Ribeiro, Rodrigo Bezerra, Audes D M Feitosa, Andrei C Sposito, José R Matos-Souza, Marilda Mazzali, Wilson Nadruz","doi":"10.1080/03007995.2025.2517699","DOIUrl":"10.1080/03007995.2025.2517699","url":null,"abstract":"<p><strong>Background: </strong>Left ventricular (LV) hypertrophy (LVH) and dysfunction are key contributors to the increased cardiovascular risk and are related to increased carotid intima-media thickness (cIMT) in hemodialysis (HD) patients. Although cIMT is considered a marker of atherosclerosis, examining its components - the intimal layer (cIT, associated with atherosclerosis) and the medial layer (cMT, linked to arteriosclerosis) - may provide deeper insights into the mechanisms of its association with LV remodeling. This study aimed to evaluate the relationship between carotid wall sublayers and LV alterations in HD patients.</p><p><strong>Methods: </strong>This cross-sectional study evaluated 102 HD patients who underwent high-resolution ultrasound to evaluate cIMT, cIT, cMT, cIT/cMT ratio, and carotid plaques. LVH, LV geometric patterns, and LV diastolic dysfunction (E/e' > 14) and systolic dysfunction (global longitudinal strain [GLS] > -16% or LV ejection fraction [LVEF] < 50%) were evaluated using echocardiography.</p><p><strong>Results: </strong>The studied sample had age = 57 ± 15 years, 59% males and median HD vintage = 17 [2, 36] months. Multivariable logistic regression analyses showed that LVH was associated with cIT (OR [95% CI] = 1.73 [1.13-2.67], <i>p</i> = .012), cIT/cMT ratio (OR [95% CI] = 1.24 [1.04-1.49], <i>p</i> = .015) and cIMT (OR [95% CI] = 1.41 [1.03-1.93], <i>p</i> = .031). Regarding LV geometric patterns, results of adjusted analyses showed that eccentric LVH was associated with cIT (OR [95% CI] = 1.64 [1.06-2.54], <i>p</i> = .027) and cIT/cMT ratio (OR [95% CI] = 1.25 [1.03-1.51]; <i>p</i> = .023). Conversely, E/e' > 14, GLS > -16% and LVEF < 50% showed no independent association with any carotid parameter.</p><p><strong>Conclusions: </strong>cIT and cIT/cMT ratio were more closely associated with LVH and eccentric LVH than cIMT or cMT in HD patients, suggesting they may be potential novel markers of cardiovascular risk in this population.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"753-759"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vortioxetine in the routine management of major depressive disorder: an analysis of European automated healthcare databases.","authors":"Frank Andersohn, Michael Cronquist Christensen, Lambert Creuwels, Ignacio Aznar-Lou, Maria Rubio-Valera, Fernie Penning-van Beest, Eline Houben, Pilar Hernandez, Katja M Hakkarainen, Elin H Reines","doi":"10.1080/03007995.2025.2505692","DOIUrl":"10.1080/03007995.2025.2505692","url":null,"abstract":"<p><strong>Objective: </strong>Vortioxetine is a multimodal antidepressant approved for the treatment of major depressive episodes. As part of the overall European risk-management plan, we aimed to fill data gaps on relevant missing information such as the extent of vortioxetine use in special populations and assessment of selected potential risks.</p><p><strong>Methods: </strong>This non-interventional post-authorization safety study used longitudinal administrative claims/medical records data from 10,358 patients newly prescribed vortioxetine in Finland, Spain, and the Netherlands (EU-PAS register: EUPAS19199).</p><p><strong>Results: </strong>Elderly patients (≥75 years) accounted for 3-14% of the assessed populations, while off-label pediatric prescribing was low (0.1-0.5%). Patients with a comorbid diagnosis of mania/hypomania accounted for 0.4-10% of the population, while patients with comorbid neurological conditions accounted for ≤3% of patients. The median prescribed daily vortioxetine dose was 10 mg and mean exposure was 72-238 days. The proportions of patients who had one of the events of interest (suicidal events, epilepsy, convulsions/seizures, severe renal or hepatic events) recorded during vortioxetine exposure were all ≤1%.</p><p><strong>Conclusion: </strong>In this European healthcare database study, the extent and characteristics of vortioxetine use were in line with clinical trial experience and the current label. Analyses of events, including those of special interest, did not raise any new safety concerns.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"867-877"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sting operations: an unfortunate necessity.","authors":"Frank Houghton","doi":"10.1080/03007995.2025.2510401","DOIUrl":"10.1080/03007995.2025.2510401","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"895-896"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of sudden blindness following mepolizumab withdrawal in EGPA.","authors":"Alessandra Marchese, Annalisa Frizzelli, Rocco Accogli, Agnese Aluia, Carolina Tessitore, Olha Bondarenko, Gaetano Caramori, Alfredo Chetta, Marina Aiello","doi":"10.1080/03007995.2025.2517693","DOIUrl":"10.1080/03007995.2025.2517693","url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis primarily affecting individuals with asthma and hypereosinophilia. Among the available treatment options for EGPA, biological therapies such as Mepolizumab have emerged for controlling eosinophilic inflammation and reducing corticosteroid dependence. Mepolizumab is a humanized monoclonal antibody that inhibits the interleukin-5 binding to its alpha-subunit receptor, which is predominantly expressed in human eosinophils. While Mepolizumab effectively reduces exacerbations and corticosteroid use, a significant proportion of patients continue to experience disease activity and relapses. Moreover, the implications of treatment discontinuation remain poorly understood.</p><p><strong>Case report: </strong>We present a clinical case of a 38 year-old patient diagnosed with anti-neutrophil cytoplasmic antibody (ANCA)-negative EGPA in 2015 based on clinical and laboratory criteria. The patient underwent a treatment regimen that included Methotrexate, Mepolizumab, and oral corticosteroids, achieving significant improvement in respiratory symptoms. However, approximately seven months after discontinuing a five-year treatment with Mepolizumab due to personal choice, the patient experienced sudden, progressively worsening and permanent blindness in the right eye.</p><p><strong>Conclusions: </strong>The permanent blindness observed in our patient may be associated with Mepolizumab withdrawal. Currently, there is limited clinical evidence regarding the effects of biologic therapy discontinuation, even in patients with stable diseases. To our knowledge, this is the first reported case of EGPA-associated blindness following Mepolizumab withdrawal. Our case underscores the need for long-term monitoring and careful risk assessment before considering treatment discontinuation, even in the absence of active symptoms.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"761-766"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world repeat screening adherence to multi-target stool DNA for colorectal cancer in a large, national Spanish-speaking population.","authors":"Mallik Greene, Timo Pew, Shrey Gohil, A Burak Ozbay, Juliana Lopez, Paul Limburg, Martha Duarte","doi":"10.1080/03007995.2025.2508764","DOIUrl":"10.1080/03007995.2025.2508764","url":null,"abstract":"<p><strong>Background: </strong>Limited English proficiency may hinder completion of colorectal cancer (CRC) screening in Spanish speakers in the US. This study evaluated CRC re-screening adherence using the multi-target stool DNA (mt-sDNA) test with Spanish language navigation, and patient characteristics associated with re-screening adherence.</p><p><strong>Methods: </strong>Data from Exact Sciences Laboratories, LLC (1 January 2023-31 December 2023) were used. Patients (45-75 years) with insurance who were shipped an mt-sDNA test during the study period, indicated Spanish as their preferred language, and had completed mt-sDNA screening with a negative result ≥2.5 years prior were included. Re-screening adherence and mean time to test return were compared among payer types; regression models were used to determine the relationship between these outcomes and patient characteristics.</p><p><strong>Results: </strong>Among 8,651 patients (45-64 years: 58.9%; female: 59.0%), partial digital with SMS only (46.3%) was the most frequent outreach type. Re-screening adherence was 80.4%, with the numerically highest rates in patients insured through managed care organizations (83.7%). Mean (standard deviation) overall time to test return from the shipment of the mt-sDNA kit to receipt of a valid test was 26.6 (38.2) days (range across payer types: 26.1 [38.9]-29.8 [41.5]). Medicare patients had a 42% higher likelihood of adherence than commercially insured patients (<i>p</i> = 0.004); patients who received SMS and email had a 59% higher likelihood of adherence than patients with no digital outreach (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Re-screening adherence of the mt-sDNA tests with Spanish language navigation was high, at 80.4%, across all payer types in patients selecting Spanish as their preferred language.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"799-807"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A response to \"Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults\".","authors":"Ekkehard Beck, Mihaela Georgieva, Nicolas Van de Velde, Oscar Patterson-Lomba, Fan Mu","doi":"10.1080/03007995.2025.2504627","DOIUrl":"10.1080/03007995.2025.2504627","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"921-923"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing hypertension management in China: care cascade insights and individual determinants from a national survey.","authors":"Yiwen Yu, Liu He, Zixuan Feng, Zhenyu Shi, Zhong Cao, Qiushi Chen, Pascal Geldsetzer, Till Bärnighausen, Ping He, Ting Yang, Simiao Chen, Chen Wang","doi":"10.1080/03007995.2025.2502674","DOIUrl":"10.1080/03007995.2025.2502674","url":null,"abstract":"<p><strong>Objectives: </strong>Hypertension is common in China, and its prevalence has been increasing. However, it remains inadequately controlled. This study examined patterns of patient attrition across the stages of hypertension management in the general population and their variations across subpopulations, and assessed the role of individual-level determinants of hypertension management. The findings would help inform clinical practice and policy decisions to enhance hypertension management in China.</p><p><strong>Methods: </strong>Using data from the 2015 China Health and Nutrition Survey among adults aged ≥18 years, we applied the framework of care cascade to hypertension management and defined three cascade stages: (1) diagnosed, (2) treated, and (3) controlled. The outcomes were based on blood pressure measurements and self-reports. Associations between cascade progression and individual characteristics were assessed using a multivariable modified Poisson regression with community fixed effects.</p><p><strong>Results: </strong>Among 3,214 hypertensive patients, 45.1% (95% confidence interval [CI]: 43.4-46.8) were diagnosed, 38.5% (36.8-40.2) received treatment, and only 13.8% (12.6-15.0) achieved blood pressure control. The proportion of undiagnosed individuals was markedly higher among the younger adults, with 82.6% (79.0-86.2) of those <45 years old and 92.6% (88.1-97.2) of those <35 years old remaining undiagnosed. Compared with those with a healthy weight, the underweight individuals were less likely to be diagnosed, with a relative risk (RR) of 0.66 (95% CI: 0.44-0.99, <i>p</i> = 0.044). By contrast, the obese patients were more likely to be diagnosed (RR [95% CI]:1.29 [1.16-1.45], <i>p</i> < 0.001), but less likely to achieve blood pressure control (RR [95% CI]: 0.58 [0.45-0.76], <i>p</i> < 0.001). In rural and economically underdeveloped areas, insured patients were less likely to achieve blood pressure control than uninsured patients.</p><p><strong>Conclusions: </strong>Our study results confirm that hypertension remains a major public health challenge in China, with its high prevalence and persistently low diagnosis, treatment, and control rates, both in the general population and across diverse demographic and socioeconomic subgroups. To address this burden, China should pay greater attention to young hypertensive adults by supporting their screening and early diagnosis. In addition, efforts should be made to strengthen therapeutic concordance among all hypertensive patients and to implement public health measures that promote healthy diets and physical activity, particularly among overweight and obese individuals. Expanding access to a broader range of antihypertensive medications, including novel agents, will also be essential for improving blood pressure control nationwide.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"741-751"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood pressure management in the first 24 hours for intracerebral hemorrhage patients on oral anticoagulant therapy.","authors":"Lindsey Selph, Teresa A Allison, Sophie Samuel","doi":"10.1080/03007995.2025.2495853","DOIUrl":"10.1080/03007995.2025.2495853","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the differences in blood pressure (BP) management and outcomes between intracerebral hemorrhage (ICH) patients on oral anticoagulant (OAC) therapy compared to those not on OAC therapy within the first 24 h of hospital admission.</p><p><strong>Methods: </strong>This retrospective cohort study included 165 ICH patients admitted to a comprehensive stroke center between July 1, 2014 and June 30, 2021. Patients were divided into two groups: those on OAC therapy (<i>n</i> = 55) and those not on OAC therapy (<i>n</i> = 110). BP measurements, including systolic BP (SBP) within 24 h of post-admission, were recorded. Clinical outcomes, such as mortality, modified Rankin Scale (mRS) scores, and length of hospital stay, were assessed. Kaplan-Meier survival analysis and Cox proportional hazards regression were used to evaluate the impact of BP management on patient outcomes.</p><p><strong>Results: </strong>No significant differences in overall survival were observed between the OAC and non-OAC groups. Although the mean SBP at 24 h was slightly higher in the OAC group (142 mmHg) compared to the non-OAC group (136 mmHg; <i>p</i> = 0.032), this did not translate into differences in mortality or functional outcomes. Higher ICH scores were associated with increased mortality risk (HR 2.01, 95% CI 1.29-3.12, <i>p</i> = 0.002). Higher GCS scores were associated with better functional outcomes (HR 0.92, 95% CI 0.85-0.99, <i>p</i> = 0.035), while BP management strategies did not show a significant impact.</p><p><strong>Conclusion: </strong>BP management in the first 24 h for ICH patients on OAC may not significantly affect mortality or functional outcomes. Current BP management strategies may be applicable to both OAC and non-OAC patients, though further research is needed to explore tailored approaches.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"733-740"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-glucose cotransporter 2 inhibitors in transthyretin amyloid cardiomyopathy: navigating potential benefits and uncertainties.","authors":"Paschalis Karakasis","doi":"10.1080/03007995.2025.2495167","DOIUrl":"10.1080/03007995.2025.2495167","url":null,"abstract":"<p><p>Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have garnered attention for their potential role in managing transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive condition characterized by significant morbidity and mortality. ATTR-CM remains underdiagnosed despite advances in diagnostic modalities. While tafamidis and acoramidis have emerged as effective therapies, residual cardiovascular risk persists, highlighting the need for adjunctive treatments. SGLT2i, initially developed as antidiabetic agents, have demonstrated cardioprotective effects in various heart failure phenotypes, including preserved and reduced ejection fractions. Emerging evidence suggests their utility in ATTR-CM, potentially addressing unmet needs, such as symptom burden, hospitalizations, and survival. Clinical studies indicate that SGLT2i reduce all-cause mortality, major adverse cardiac events (MACE), and heart failure hospitalizations, with benefits extending to cardiovascular mortality and improved functional status. Moreover, these agents appear to mitigate arrhythmic complications, evidenced by reduced cardioversion procedures and antiarrhythmic therapy requirements. Observational studies also highlight the potential synergy of SGLT2i with tafamidis, suggesting additive benefits in addressing amyloid deposition and heart failure. However, limitations, including the absence of randomized controlled trials, immortal time bias, and population heterogeneity, necessitate further research. Future directions involve elucidating mechanisms of action, exploring personalized treatment strategies, and leveraging big data analytics for real-world insights. SGLT2i's potential to transform ATTR-CM management underscores their promise, though robust trials are imperative to validate findings and optimize clinical applications.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"657-661"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}